Department of Neurology, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea.
J Korean Med Sci. 2022 Mar 14;37(10):e50. doi: 10.3346/jkms.2022.37.e50.
As coronavirus disease 2019 (COVID-19) has spread worldwide, the rate of COVID-19 vaccination uptake is encouraging. Neurological complications associated with COVID-19 vaccines such as stroke, Guillain-Barré syndrome, and Bell's palsy have been reported. Recently, late-onset myasthenia gravis (MG) following COVID-19 vaccination has been reported. To date, however, there has been no evidence of increased risk of early-onset MG following COVID-19. Here, we report a case of a patient with new-onset MG that arose after receiving a COVID-19 vaccine. A 33-year-old woman suddenly experienced generalized weakness and diplopia on the evening she had received the second dose of the Pfizer-BioNTech COVID-19 vaccine. The temporal relationship suggests that this new-onset MG is related to the vaccination. It also implies that COVID-19 vaccination could trigger early-onset MG symptoms in patients at risk of MG.
随着 2019 年冠状病毒病（COVID-19）在全球范围内传播，COVID-19 疫苗接种率令人鼓舞。与 COVID-19 疫苗相关的神经系统并发症，如中风、吉兰-巴雷综合征和贝尔麻痹，已有报道。最近，COVID-19 疫苗接种后出现迟发性重症肌无力（MG）的病例也有报道。然而，目前尚无 COVID-19 后早发性 MG 风险增加的证据。在这里，我们报告了一例 COVID-19 疫苗接种后发生新发 MG 的病例。一名 33 岁女性在接种辉瑞-生物科技公司 COVID-19 疫苗第二剂的当晚突然出现全身无力和复视。时间关系提示，这种新发 MG 与疫苗接种有关。这也意味着 COVID-19 疫苗接种可能会引发 MG 风险患者的早发性 MG 症状。
